The Multiple Myeloma Research Foundation does everything possible to make clinical trials faster and easier from start to finish. The result will be more effective treatments that are, ultimately, tailored to the individual patient.

We build our trials around robustly validated compounds and combinations that show potential for treating patients. This reduces time spent on drugs destined to fail in the clinic and ensures that our resources are directed toward drugs with the best chance of effectively treating patients.

By analyzing each patient's individual DNA profile, we are able to help patients most likely to benefit from a specific compound find the best clinical trial. We study the right drugs in the right patients.

We also study patients' tissue to determine which patients respond to what treatments and why (called correlative science studies). Findings from correlative studies are critical in identifying patients for whom the compound under study is most effective. This information can be used to inform and redirect new treatment strategies.